Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17482860 | 0.98 | BACE1 (0.36) | BACE1CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL17482850 | 0.96 | BACE1 (0.39) | BACE1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL17482875 | 0.94 | BACE1 (0.37) | BACE1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL17482857 | 0.94 | MAOA (0.34) | BACE1MAOAMAOBACHE | |
| SCHEMBL17482848 | 0.94 | BACE1 (0.38) | BACE1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL17482876 | 0.92 | BACE1 (0.36) | BACE1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL17482864 | 0.92 | MAOA (0.33) | MAOAMAOBACHE | |
| SCHEMBL17482866 | 0.92 | MAOA (0.34) | MAOAMAOBACHE | |
| SCHEMBL17482865 | 0.92 | BACE1 (0.35) | BACE1CYP11B2CYP11B1PDK2MAPT | |
| SCHEMBL17482855 | 0.89 | BACE1 (0.36) | BACE1CYP11B2CYP11B1CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160035986-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-02-04 | — | — | US | disclosed |
| US-20160035986-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160035986-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, CCNA1 | BACE1 533/4885CYP11B2 1724/4885CYP11B1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.